Huntsville, Ala. November 13, 2017 – iCubate®, Inc., an innovative molecular diagnostic device company, announced today that it will host a workshop presentation at the Association of Molecular Pathology (AMP) meeting in Salt Lake City, Utah. The presentation will be on Wednesday, November 15 at 4 pm at the Calvin L. Rampton Salt Palace Convention Center.
The presentation, titled “Clinical Application of the iCubate Gram-Positive Cocci (iC-GPC) Assay,” will feature key opinion leaders and iCubate leadership. The iC-GPC Assay™, used for the rapid detection of pathogenic bacteria associated with bloodstream infections, earned U.S. FDA clearance earlier this year.
Among those participating in the workshop presentation are:
- Paul A. Granato, Ph.D., DABMM, FAMM, Professor Emeritus of Pathology, SUNY Upstate Medical University and Director of Microbiology, Laboratory Alliance of Central New York
- Stephen Young, Ph.D. D(ABMM), Professor Emeritus of Pathology, University of New Mexico and Director of Research and Clinical Trials, Tricore Reference Laboratories
- Fran White, Founder and President of MDC Associates, an FDA Regulatory and Quality Assurance Consulting Firm
- Matt Conover, Ph.D., iCubate, Inc. Molecular Biologist and Assay Developer
“This workshop will be an interesting and informative presentation on the qualities of the iCubate System and FDA-cleared assay,” said Dr. Paul Granato. “Performance data of the assay, user experience of the platform and iCubate’s product pipeline will all be addressed.”
In addition to the AMP Corporate Workshop, iCubate invites attendees to visit the iCubate Exhibit at booth #1009 throughout the week. On Saturday, November 18 at 9:45 am until 10:45 am, Dr. Conover will present findings on iCubate’s next assay, the iC-Gram Negative (GN) panel.
“All of us at iCubate are looking forward to this presentation and all of the activities of AMP 2017. Presenting in Salt Lake City this week allows us to highlight the outstanding qualities of iCubate’s recently FDA cleared platform and iC-GPC Assay,” said Carter Wells, iCubate’s Chief Executive Officer.
The iC-GPC Assay™ is a multiplexed, in vitro diagnostic test for the identification of potentially pathogenic bacteria and clinically significant resistance markers, to aid in the diagnosis of bacterial bloodstream infections (BSI).
For further information about iCubate while attending AMP, please contact Callie Spengler (email@example.com; 256.327.0532)
The iCubate platform and assay provides results up to 48 hours faster than conventional methods. The iC-GPC Assay™ provides identification of five of the most common gram-positive organisms associated with gram-positive bacteremia, including Staphylococcus aureus. Additionally, the assay identifies three clinically relevant antibiotic resistance markers specific to methicillin-resistant Staphylococcus and vancomycin-resistant Enterococcus.
About iCubate®: iCubate®, Incorporated is a privately-held molecular diagnostic company located in the HudsonAlpha Institute for Biotechnology. iCubate’s mission is to provide a personal diagnosis having an immediate and intelligent impact on patient lives. The integrated iCubate System (iC-System™) enables extraction, multiplexed amplification and detection automatically in a closed and disposable cassette. iCubate provides a sample in-answer out diagnostic test with highly multiplexing ARM-PCR technology and a user friendly, flexible platform. Other iCubate products are available world-wide for non-clinical, research-use only in the areas of health, agriculture, food safety and defense. See icubate.com for more information.
Forward-Looking Statements: Some statements in this press release may be “forward-looking statements”. iCubate® cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. iCubate undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.